Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ResMed head passes mantle to son

This article was originally published in Clinica

Executive Summary

Respiratory disorder therapy firm ResMed's founder, chairman and CEO Dr Peter Farrell is passing the role of chief executive over to his son Michael Farrell, who is currently head of the firm's Americas operations. Mr Farrell Jnr has been at ResMed since 2000 and has held a number of senior sales and business development roles. Robert Douglas, the current chief operating officer, will assume the additional responsibility of president. Dr Farrell will remain executive chairman and work with his son and Mr Douglas on an as-needed basis through the end of 2013, after which he will become non-executive chairman. Mr Farrell's existing role of president, Americas, will be taken up by ResMed's current chief strategy officer and president of ventures and initiatives strategic unit, Dr Jim Hollingshead.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT100025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel